A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.

Yiming Cheng,Ying Ye,Allison Gaudy,Atalanta Ghosh,Yongjun Xue, Alice Wang,Simon Zhou,Yan Li

Clinical pharmacology : advances and applications（2023）

Cited 0|Views33

No score

Abstract

In summary, 1 mg single oral dose of iberdomide was generally well-tolerated. HI (mild, moderate or severe) had no clinically relevant impact on iberdomide PK and therefore, no dose adjustment is warranted.

Translated text

Key words

hepatic impairment,iberdomide,pharmacokinetics

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined